{"id":752151,"date":"2023-04-27T10:54:38","date_gmt":"2023-04-27T14:54:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/"},"modified":"2023-04-27T10:54:38","modified_gmt":"2023-04-27T14:54:38","slug":"gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/","title":{"rendered":"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8211;<\/em><br \/>\n        <em>L<\/em><br \/>\n        <em>ive moderated webcast w<\/em><br \/>\n        <em>i<\/em><br \/>\n        <em>th members of the GRI Bio management team on Wednesday, May 3<\/em><br \/>\n        <sup><br \/>\n          <em>rd<\/em><br \/>\n        <\/sup><br \/>\n        <em>at 2:00 PM ET<\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <strong>LA JOLLA, CA, April  27, 2023  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0EQlmpgV_D8YhWCTeZ0PFq9f9fual3Ss0D8K8gmfKgUXCyZar1dToqAxkx1YAB0DZuZ4CvNzQCWgavg6kEHA_g==\" rel=\"nofollow noopener\" target=\"_blank\">GRI Bio, Inc.<\/a> (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will present at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nRMkD46OeRDNsAtSm3SMtez4rZZhtQmv2IJvNKxNZPEFaB-U-EQivCCjIk_0wugTe3PXb6ifPR6Rdm4LMfwexJ5lf67pFeB9UMhCEHj5XLIS3MX4VnWxEUUZXXPR50jYDeiNYMDlPh1Hzaa1maUWm-jV8XfR_hhf3XqFZkYpQv4cTOv7Z5utJDnqA3LYd5Rk\" rel=\"nofollow noopener\" target=\"_blank\">Virtual Investor New to the Street Event<\/a> on Wednesday, May 3, 2023 at 2:00 PM ET.<\/p>\n<p align=\"justify\">As part of the event, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OPO0mNFOgfHDvzc4FGCXmPpivjWrRaRlCkS5u_rLaz5Z1iEmZ1oe_NkQ_46vDBKp4q8HCcf0fSZ8vM68plWrWACrjycxC6xWx4pjkw8QLCkIloppufl346HNOnJaxnQuQ7vJ6EfcmAbmIT9j3FCSJw==\" rel=\"nofollow noopener\" target=\"_blank\">Marc Hertz, President and Chief Executive Officer<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sGcT1FEftH2VhcOW97r5qB7vTXE4UvxG-5hRiVpuF1_XPfdHyTWGcM79Rh5mPqkxcEXi_ImsrVLAKPIJnkMsMfgP0lEQ0vXq1x8t0Tjgzkk2PBTsRhG8543EMcU0jBtp\" rel=\"nofollow noopener\" target=\"_blank\">Albert Agro, Chief Medical Officer<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=siTGcqH5mSo8RE0c5GiOl3hdL_PXNsfN98eqgIjE6PD47-hK6AhfbHF1jCJ1GWlyrYjL9wbVECzRm7J4qm6nYcDdHviUcWLjmS_7WZHvTRRO7SMKXU3ADO472lrjVd-8\" rel=\"nofollow noopener\" target=\"_blank\">Vipin Kumar, Chief Scientific Officer<\/a> of GRI Bio will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.<\/p>\n<p align=\"justify\">A <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gFKfgUnrKnabVp98yLB4p4x3SD-82QFbsE4_VM9GqbIpjivwzON3mG2UeU1LqltchiO09IzKmUoN9GekrqXwsFU273_KFRgjoAzpWv2bjI2lEr9HZAmjv6SZ3sB5xXLYPYRyZFQHDZEOWIB4vDgOt20cR_eOmzcI8GCZ8FqgJpg=\" rel=\"nofollow noopener\" target=\"_blank\">live video webcast<\/a> of the presentation will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PK29QpZV81IZeUMmxtbxG8wDiY2z_927Se9oHnlpeEyu1L2DUk_4nKA80n4VXPK1BaMvSTAg263nyXc2EdOkig==\" rel=\"nofollow noopener\" target=\"_blank\">Events<\/a> page of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QIsVOL16dE_uSjW00AYHg-IKlUeS6liz0_LlqWZAokzvClHDL1oCyId-n2lVvIYgzTZOjJzy7vVd2SbYJ5NCaA==\" rel=\"nofollow noopener\" target=\"_blank\">Investors<\/a> section of the Company\u2019s website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=60cTwHi6aRq_XtlHf8sRwb5bnLPVI3TPyboaQrVDrfjCb4lgpCEDwJrFS0rLJBC8B1wNPWAYqswZT-w-r5unKA==\" rel=\"nofollow noopener\" target=\"_blank\">www.gribio.com<\/a>). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.<br \/><strong>About GRI Bio, Inc.<\/strong><\/p>\n<p align=\"justify\">GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio\u2019s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (\u201ciNKT\u201d) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio\u2019s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel Type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions. These forward-looking statements are based on the Company\u2019s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company\u2019s expectations with respect to development and commercialization of the Company\u2019s product candidates, the initiation or completion of clinical trials, the potential benefits and impact of the Company\u2019s product candidates and the related timing of regulatory approvals, if any. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company\u2019s common stock on Nasdaq; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company\u2019s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for their products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company\u2019s products and services, and its ability to serve those markets, either alone or in partnership with others; (9) inaccuracy in the Company\u2019s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; (10) the Company\u2019s financial performance; and (11) other risks and uncertainties indicated from time to time in the Company\u2019s filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), including the risks and uncertainties described in the \u201cRisk Factors\u201d section of the Company\u2019s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and subsequently filed reports and in the section entitled \u201cRisks Related to GRI\u201d in the Company\u2019s Prospectus\/Proxy Statement\/Information Statement filed with the SEC on March 8, 2023. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>\n        <strong>Investor <\/strong><br \/>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(833) 475-8247<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cZvnr-vIAgJz0POAISsSjjMcnYpH-Jl4NnrS5DOTiZaLATfGT3O4OvzBVaAoAvVORxfhaS2OgXsXDAhZ7lCpOw==\" rel=\"nofollow noopener\" target=\"_blank\">GRI@jtcir.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmJkNDgxZjgtMWNiMC00ZjhkLWI1MjctYTQ1ODdkOWJjNmMwLTUwMDA3NTQ4OA==\/tiny\/GRI-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; L ive moderated webcast w i th members of the GRI Bio management team on Wednesday, May 3 rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, May 3, 2023 at 2:00 PM ET. As part of the event, Marc Hertz, President and Chief Executive Officer, Albert Agro, Chief Medical Officer and Vipin Kumar, Chief Scientific Officer of GRI Bio will provide a corporate &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-752151","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; L ive moderated webcast w i th members of the GRI Bio management team on Wednesday, May 3 rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, May 3, 2023 at 2:00 PM ET. As part of the event, Marc Hertz, President and Chief Executive Officer, Albert Agro, Chief Medical Officer and Vipin Kumar, Chief Scientific Officer of GRI Bio will provide a corporate &hellip; Continue reading &quot;GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T14:54:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event\",\"datePublished\":\"2023-04-27T14:54:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/\"},\"wordCount\":853,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/\",\"name\":\"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==\",\"datePublished\":\"2023-04-27T14:54:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/","og_locale":"en_US","og_type":"article","og_title":"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event - Market Newsdesk","og_description":"&#8211; L ive moderated webcast w i th members of the GRI Bio management team on Wednesday, May 3 rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, May 3, 2023 at 2:00 PM ET. As part of the event, Marc Hertz, President and Chief Executive Officer, Albert Agro, Chief Medical Officer and Vipin Kumar, Chief Scientific Officer of GRI Bio will provide a corporate &hellip; Continue reading \"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-27T14:54:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event","datePublished":"2023-04-27T14:54:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/"},"wordCount":853,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/","name":"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==","datePublished":"2023-04-27T14:54:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjU1MSM1NTYwMTcwIzUwMDA3NTQ4OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-nasdaq-gri-to-present-at-the-virtual-investor-new-to-the-street-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=752151"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752151\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=752151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=752151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=752151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}